Literature DB >> 25309062

Impact of proteolytic enzymes in colorectal cancer development and progression.

László Herszényi1, Loránd Barabás1, István Hritz1, Gábor István1, Zsolt Tulassay1.   

Abstract

Tumor invasion and metastasis is a highly complicated, multi-step phenomenon. In the complex event of tumor progression, tumor cells interact with basement membrane and extracellular matrix components. Proteolytic enzymes (proteinases) are involved in the degradation of extracellular matrix, but also in cancer invasion and metastasis. The four categories of proteinases (cysteine-, serine-, aspartic-, and metalloproteinases) are named and classified according to the essential catalytic component in their active site. We and others have shown that proteolytic enzymes play a major role not only in colorectal cancer (CRC) invasion and metastasis, but also in malignant transformation of precancerous lesions into cancer. Tissue and serum-plasma antigen concentrations of proteinases might be of great value in identifying patients with poor prognosis in CRC. Our results, in concordance with others indicate the potential tumor marker impact of proteinases for the early diagnosis of CRC. In addition, proteinases may also serve as potential target molecules for therapeutic agents.

Entities:  

Keywords:  Adenoma; Biomarker; Cathepsin; Colorectal cancer; Invasion; Matrix metalloproteinase; Metastasis; Plasminogen activator; Prognosis; Proteinase

Mesh:

Substances:

Year:  2014        PMID: 25309062      PMCID: PMC4188883          DOI: 10.3748/wjg.v20.i37.13246

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  177 in total

Review 1.  Natural and engineered plasmin inhibitors: applications and design strategies.

Authors:  Joakim E Swedberg; Jonathan M Harris
Journal:  Chembiochem       Date:  2012-01-11       Impact factor: 3.164

2.  Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by hypoxia-inducible factor-1α.

Authors:  Florian Schelter; Birgit Halbgewachs; Petra Bäumler; Caroline Neu; Agnes Görlach; Florian Schrötzlmair; Achim Krüger
Journal:  Clin Exp Metastasis       Date:  2010-10-30       Impact factor: 5.150

3.  Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patients.

Authors:  J Halamkova; I Kiss; Z Pavlovsky; J Tomasek; J Jarkovsky; Z Cech; S Tucek; L Hanakova; M Moulis; J Zavrelova; M Man; P Benda; O Robek; Z Kala; M Penka
Journal:  Neoplasma       Date:  2011       Impact factor: 2.575

4.  Matrix metalloproteinase-9 is associated with relapse and prognosis of patients with colorectal cancer.

Authors:  Dake Chu; Zhengwei Zhao; Yi Zhou; Yunming Li; Jipeng Li; Jianyong Zheng; Qingchuan Zhao; Weizhong Wang
Journal:  Ann Surg Oncol       Date:  2011-04-01       Impact factor: 5.344

5.  Matrix metalloproteinase-9 expression in the normal mucosa-adenoma-dysplasia-adenocarcinoma sequence of the colon.

Authors:  László Herszényi; Ferenc Sipos; Orsolya Galamb; Norbert Solymosi; István Hritz; Pál Miheller; Lajos Berczi; Béla Molnár; Zsolt Tulassay
Journal:  Pathol Oncol Res       Date:  2008-03-18       Impact factor: 3.201

6.  TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid.

Authors:  Nanna M Sørensen; Per Byström; Ib J Christensen; Ake Berglund; Hans Jørgen Nielsen; Nils Brünner; Bengt Glimelius
Journal:  Clin Cancer Res       Date:  2007-07-15       Impact factor: 12.531

7.  Cathepsin B and cathepsin D expression in the progression of colorectal adenoma to carcinoma.

Authors:  Maroulio Talieri; Sofia Papadopoulou; Andreas Scorilas; Dimitrios Xynopoulos; Niki Arnogianaki; George Plataniotis; Julia Yotis; Niki Agnanti
Journal:  Cancer Lett       Date:  2004-03-08       Impact factor: 8.679

8.  Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1.

Authors:  M V Cubellis; T C Wun; F Blasi
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598

9.  Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer.

Authors:  S Ganesh; C F Sier; M M Heerding; J H van Krieken; G Griffioen; K Welvaart; C J van de Velde; J H Verheijen; C B Lamers; H W Verspaget
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Differential Impact of Cysteine Cathepsins on Genetic Mouse Models of De novo Carcinogenesis: Cathepsin B as Emerging Therapeutic Target.

Authors:  Thomas Reinheckel; Christoph Peters; Achim Krüger; Boris Turk; Olga Vasiljeva
Journal:  Front Pharmacol       Date:  2012-07-11       Impact factor: 5.810

View more
  16 in total

1.  Unique insight into microenvironmental changes in colorectal cancer: Ex vivo assessment of matrix metalloprotease-mediated molecular changes in human colorectal tumor tissue and corresponding non-neoplastic adjacent tissue.

Authors:  Nicholas Willumsen; Cecilie L Bager; Anne-Christine Bay-Jensen; Stephanie N Kehlet; Henrik Harling; Diana J Leeming; Morten A Karsdal; Lars N Jorgensen
Journal:  Oncol Lett       Date:  2017-03-23       Impact factor: 2.967

2.  Implication of Hepsin from Primary Tumor in the Prognosis of Colorectal Cancer Patients.

Authors:  David Zaragoza-Huesca; Andrés Nieto-Olivares; Francisco García-Molina; Guillermo Ricote; Sofía Montenegro; Manuel Sánchez-Cánovas; Pedro Garrido-Rodríguez; Julia Peñas-Martínez; Vicente Vicente; Francisco Martínez; María Luisa Lozano; Alberto Carmona-Bayonas; Irene Martínez-Martínez
Journal:  Cancers (Basel)       Date:  2022-06-24       Impact factor: 6.575

3.  Expression of prokineticin-receptor2(PK-R2) is a new prognostic factor in human colorectal cancer.

Authors:  Takanori Goi; Hidetaka Kurebayashi; Yuki Ueda; Takayuki Naruse; Toshiyuki Nakazawa; Kenji Koneri; Yasuo Hirono; Kanji Katayama; Akio Yamaguchi
Journal:  Oncotarget       Date:  2015-10-13

4.  Overexpression of IRS-4 Correlates with Procaspase 3 Levels in Tumoural Tissue of Patients with Colorectal Cancer.

Authors:  Patricia Sanmartín-Salinas; Luis G Guijarro
Journal:  J Oncol       Date:  2018-10-16       Impact factor: 4.375

5.  Effect of Cellular Location of Human Carboxylesterase 2 on CPT-11 Hydrolysis and Anticancer Activity.

Authors:  Yuan-Ting Hsieh; Hsuan-Pei Lin; Bing-Mae Chen; Ping-Ting Huang; Steve R Roffler
Journal:  PLoS One       Date:  2015-10-28       Impact factor: 3.240

6.  Excessive collagen turnover products are released during colorectal cancer progression and elevated in serum from metastatic colorectal cancer patients.

Authors:  S N Kehlet; R Sanz-Pamplona; S Brix; D J Leeming; M A Karsdal; V Moreno
Journal:  Sci Rep       Date:  2016-07-28       Impact factor: 4.379

7.  Knock-down of Hdj2/DNAJA1 co-chaperone results in an unexpected burst of tumorigenicity of C6 glioblastoma cells.

Authors:  Darya A Meshalkina; Maxim A Shevtsov; Anatoliy V Dobrodumov; Elena Y Komarova; Irina V Voronkina; Vladimir F Lazarev; Boris A Margulis; Irina V Guzhova
Journal:  Oncotarget       Date:  2016-04-19

8.  Identification of breast cancer recurrence risk factors based on functional pathways in tumor and normal tissues.

Authors:  Xiujie Chen; Lei Liu; YunFeng Wang; Bo Liu; Diheng Zeng; Qing Jin; MengJian Li; DeNan Zhang; Qiuqi Liu; Hongbo Xie
Journal:  Oncotarget       Date:  2017-03-28

Review 9.  The Impact of Human Papilloma Viruses, Matrix Metallo-Proteinases and HIV Protease Inhibitors on the Onset and Progression of Uterine Cervix Epithelial Tumors: A Review of Preclinical and Clinical Studies.

Authors:  Giovanni Barillari; Paolo Monini; Cecilia Sgadari; Barbara Ensoli
Journal:  Int J Mol Sci       Date:  2018-05-09       Impact factor: 5.923

10.  Antiproliferative and antimigratory effects of 3-(4-substituted benzyl)-5- isopropyl-5-phenylhydantoin derivatives in human breast cancer cells.

Authors:  Ana Obradović; Miloš Matić; Branka Ognjanović; Predrag Đurđević; Emilija Marinković; Gordana Ušćumlić; Bojan Božić; Biljana Božić Nedeljković
Journal:  Saudi Pharm J       Date:  2020-01-24       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.